Stem Cell/Cord Blood Banking Market Report 2026

The stem cell/cord blood banking market size has grown rapidly in recent years. It will grow from $13.33 billion in 2025 to $15.01 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increase in private banking adoption, medical awareness growth, improved storage technologies, regulatory frameworks, marketing initiatives.

The stem cell/cord blood banking market size is expected to see rapid growth in the next few years. It will grow to $24.47 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to expanded therapeutic uses, affordability improvements, emerging market penetration, partnerships with hospitals, long-term storage demand. Major trends in the forecast period include private cord blood storage growth, hybrid public-private banking models, expanded stem cell applications, improved cryogenic storage, consumer awareness campaigns.

The increasing prevalence of chronic diseases is expected to drive growth in the stem cell/cord blood banking market in the coming years. Chronic diseases are illnesses that last three months or longer and can worsen over time. As many chronic conditions lack effective treatments, the regenerative potential of stem cells and cord blood is being increasingly explored for therapeutic purposes. The expansion of stem cell transplants, personalized medicine, and clinical research into novel therapies for chronic diseases is boosting demand for banking services. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, over 35 million new cancer cases would occur, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases is fueling growth in the stem cell and cord blood banking market.

Key companies in the stem cell/cord blood banking market are focusing on developing peripheral blood stem cell (PBSC) processing and storage services to gain a competitive advantage. PBSC processing and storage involve the collection, testing, processing, and cryopreservation of hematopoietic stem cells (HSCs) obtained from a patient’s peripheral blood. For instance, in February 2023, Cordlife Group Limited, a Singapore-based healthcare company, launched a new PBSC processing and storage service in Singapore. This service supports patients requiring hematopoietic stem cell transplantation for blood-related diseases, including leukemia, myeloma, and lymphoma. Through its collaboration with the Centre for Clinical Haematology (CFCH), eligible patients undergo stem cell mobilization and harvesting, while Cordlife manages the subsequent processing, testing, and cryopreservation of PBSCs. This service aims to improve treatment outcomes for patients requiring HSC transplants and expand Cordlife’s banking offerings in Singapore.

In July 2024, Cytomed Therapeutics, a Singapore-based biopharmaceutical company, acquired Cellsafe International Sdn Bhd for US $490,000. This acquisition is intended to strengthen Cytomed’s strategy for developing allogeneic, off-the-shelf donor-derived gamma delta (γδ) T cell therapies for treating solid and liquid cancers. Cellsafe International Sdn Bhd, based in Malaysia, is a cord blood banking company.

Major companies operating in the stem cell/cord blood banking market are Cryo-Cell International Inc, Esperite NV, Americord Registry LLC, China Cord Blood Corporation, Cordlife Group Ltd, CordVida, Cryo Stemcell, ReeLabs Pvt Ltd, Smart Cells International Ltd, Stemade Biotech Pvt Ltd, ViaCord Inc, LifeCell International, Cryoviva Biotech Pvt Ltd, Cord Blood America Inc, StemCyte Inc, Cord Blood Registry Systems Inc, Healthbanks Biotech Usa Inc, Cryo-save Private Ltd, New York Cord Blood Center, CryoHoldco, Vita 34 International AG, Reliance Life Sciences Pvt Ltd, Maze Cord Blood Laboratories, Cells4Life Group LLP.

North America was the largest region in the stem cell/cord blood banking market in 2025. Western Europe was the second largest region in the stem cell/cord blood banking market analysis. The regions covered in the stem cell/cord blood banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the stem cell and cord blood banking market by raising the cost of imported cryogenic storage systems, processing equipment, testing kits, and laboratory consumables. Public and private banks in Asia-Pacific and developing regions are particularly impacted due to dependence on global suppliers. These higher costs can increase storage and processing fees. However, tariffs are encouraging local equipment manufacturing and service infrastructure, improving long-term operational stability.

The stem cell/cord blood banking market research report is one of a series of new reports that provides stem cell/cord blood banking market statistics, including stem cell/cord blood banking industry global market size, regional shares, competitors with a stem cell/cord blood banking market share, detailed stem cell/cord blood banking market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell/cord blood banking industry. This stem cell/cord blood banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell or cord blood banking is the process of collecting and storing stem cells or blood from the umbilical cord for potential future medical use. By preserving stem cells from the placenta and umbilical cord, cord blood banking can potentially save lives and help treat injuries or diseases later on.

The main cell types in stem cell/cord blood banking include adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a rare group of cells present in the body throughout most of postnatal life and can develop into a limited range of mature cell types that make up the tissues where they reside. Services provided include collection, processing, analysis, and storage, and are offered through various types of banks, such as private and public banks. Applications of stem cell/cord blood banking include treatment for leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, and other conditions.

The stem cell/cord blood banking global market includes revenues earned by entities by providing services such as cryopreservation and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.